nodes	percent_of_prediction	percent_of_DWPC	metapath
Vapreotide—SSTR5—pituitary gland—polycystic ovary syndrome	0.0365	0.246	CbGeAlD
Vapreotide—SSTR5—endocrine gland—polycystic ovary syndrome	0.0283	0.191	CbGeAlD
Vapreotide—SSTR2—pituitary gland—polycystic ovary syndrome	0.0235	0.159	CbGeAlD
Vapreotide—SSTR2—endocrine gland—polycystic ovary syndrome	0.0182	0.123	CbGeAlD
Vapreotide—TACR1—adipose tissue—polycystic ovary syndrome	0.0156	0.105	CbGeAlD
Vapreotide—TACR1—adrenal gland—polycystic ovary syndrome	0.014	0.0943	CbGeAlD
Vapreotide—TACR1—endocrine gland—polycystic ovary syndrome	0.0121	0.0817	CbGeAlD
Vapreotide—SSTR2—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00148	0.00173	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00147	0.00172	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00146	0.00172	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00146	0.00171	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00145	0.0017	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—PTGER3—polycystic ovary syndrome	0.00144	0.00168	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—LHCGR—polycystic ovary syndrome	0.00144	0.00168	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—ADRA1D—polycystic ovary syndrome	0.00143	0.00168	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.0014	0.00164	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—NPB—polycystic ovary syndrome	0.0014	0.00164	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—ADRA1B—polycystic ovary syndrome	0.0014	0.00164	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00138	0.00163	CbGpPWpGaD
Vapreotide—SSTR5—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.00138	0.00162	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00135	0.00159	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00134	0.00158	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—PTAFR—polycystic ovary syndrome	0.00134	0.00158	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00134	0.00157	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00133	0.00157	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00132	0.00155	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—ADRA1D—polycystic ovary syndrome	0.0013	0.00153	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.0013	0.00152	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00129	0.00152	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—NPB—polycystic ovary syndrome	0.00129	0.00151	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00128	0.0015	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—polycystic ovary syndrome	0.00128	0.0015	CbGpPWpGaD
Vapreotide—SSTR2—G alpha (i) signalling events—POMC—polycystic ovary syndrome	0.00127	0.0015	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00127	0.00149	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—PDE3B—polycystic ovary syndrome	0.00127	0.00149	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—ADRA1B—polycystic ovary syndrome	0.00127	0.00149	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00126	0.00148	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00126	0.00148	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.00125	0.00147	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00124	0.00146	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00124	0.00145	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.00124	0.00145	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00123	0.00144	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.00122	0.00143	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.0012	0.00141	CbGpPWpGaD
Vapreotide—TACR1—Peptide ligand-binding receptors—POMC—polycystic ovary syndrome	0.00119	0.0014	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00118	0.00138	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—GHRL—polycystic ovary syndrome	0.00118	0.00138	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.00117	0.00138	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00117	0.00137	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00117	0.00137	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.00117	0.00137	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—FLT4—polycystic ovary syndrome	0.00116	0.00136	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—LHB—polycystic ovary syndrome	0.00116	0.00136	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—FSHR—polycystic ovary syndrome	0.00116	0.00136	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—PDE3B—polycystic ovary syndrome	0.00115	0.00135	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.00115	0.00135	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.00114	0.00134	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.00113	0.00133	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00112	0.00132	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.00111	0.0013	CbGpPWpGaD
Vapreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.0011	0.00129	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00109	0.00128	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—SCT—polycystic ovary syndrome	0.00109	0.00128	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.00108	0.00126	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.00108	0.00126	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00106	0.00124	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—ADRA1A—polycystic ovary syndrome	0.00106	0.00124	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—FSHR—polycystic ovary syndrome	0.00105	0.00123	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.00104	0.00122	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.00103	0.00121	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—ADRB3—polycystic ovary syndrome	0.00102	0.0012	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—NPB—polycystic ovary syndrome	0.00102	0.00119	CbGpPWpGaD
Vapreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.00101	0.00119	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.00101	0.00118	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—LHB—polycystic ovary syndrome	0.00101	0.00118	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—INHBB—polycystic ovary syndrome	0.001	0.00118	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—GNRH1—polycystic ovary syndrome	0.000983	0.00115	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.000978	0.00115	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—ADRB2—polycystic ovary syndrome	0.000973	0.00114	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—ADRA1A—polycystic ovary syndrome	0.000961	0.00113	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000951	0.00112	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—SCT—polycystic ovary syndrome	0.000943	0.00111	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000938	0.0011	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—INHBB—polycystic ovary syndrome	0.000927	0.00109	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—ADRB3—polycystic ovary syndrome	0.000925	0.00109	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PLEKHG5—polycystic ovary syndrome	0.000919	0.00108	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000914	0.00107	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—LHB—polycystic ovary syndrome	0.000914	0.00107	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—GNAS—polycystic ovary syndrome	0.000902	0.00106	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—MTNR1B—polycystic ovary syndrome	0.000899	0.00106	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—GNRH1—polycystic ovary syndrome	0.000893	0.00105	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—VEGFA—polycystic ovary syndrome	0.000875	0.00103	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000865	0.00102	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—SCT—polycystic ovary syndrome	0.000856	0.001	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000854	0.001	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—LHCGR—polycystic ovary syndrome	0.000848	0.000995	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PTGER3—polycystic ovary syndrome	0.000848	0.000995	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000844	0.00099	CbGpPWpGaD
Vapreotide—SSTR5—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000836	0.000981	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.00083	0.000975	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—MTNR1B—polycystic ovary syndrome	0.000817	0.000959	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000803	0.000942	CbGpPWpGaD
Vapreotide—TACR1—Class A/1 (Rhodopsin-like receptors)—POMC—polycystic ovary syndrome	0.000798	0.000936	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PTAFR—polycystic ovary syndrome	0.000793	0.000931	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—FSHR—polycystic ovary syndrome	0.000788	0.000925	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000781	0.000917	CbGpPWpGaD
Vapreotide—SSTR2—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000772	0.000906	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—ADRA1D—polycystic ovary syndrome	0.00077	0.000903	CbGpPWpGaD
Vapreotide—SSTR2—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.000769	0.000902	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000766	0.000899	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—FST—polycystic ovary syndrome	0.000761	0.000893	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000757	0.000888	CbGpPWpGaD
Vapreotide—TACR1—Spinal Cord Injury—IL6—polycystic ovary syndrome	0.000757	0.000888	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000752	0.000882	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—ADRA1B—polycystic ovary syndrome	0.000749	0.000879	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—LHB—polycystic ovary syndrome	0.000743	0.000872	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000741	0.00087	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—INHBB—polycystic ovary syndrome	0.00073	0.000856	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000726	0.000852	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000721	0.000846	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000703	0.000825	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—FST—polycystic ovary syndrome	0.000702	0.000824	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000702	0.000824	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.000698	0.00082	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—SCT—polycystic ovary syndrome	0.000696	0.000817	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000694	0.000814	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000687	0.000807	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—LHB—polycystic ovary syndrome	0.000686	0.000805	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PDE3B—polycystic ovary syndrome	0.000681	0.0008	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.00067	0.000787	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—GHRL—polycystic ovary syndrome	0.000664	0.00078	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000664	0.000779	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000653	0.000766	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000649	0.000762	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.000648	0.00076	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000647	0.00076	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—SCT—polycystic ovary syndrome	0.000642	0.000754	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000637	0.000748	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000634	0.000744	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—FSHR—polycystic ovary syndrome	0.00062	0.000728	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000613	0.000719	CbGpPWpGaD
Vapreotide—TACR1—GPCR ligand binding—POMC—polycystic ovary syndrome	0.000608	0.000713	CbGpPWpGaD
Vapreotide—TACR1—SIDS Susceptibility Pathways—IL6—polycystic ovary syndrome	0.000605	0.00071	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000604	0.000709	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—GHRL—polycystic ovary syndrome	0.000603	0.000708	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000602	0.000707	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—RBP4—polycystic ovary syndrome	0.000597	0.000701	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000596	0.000699	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000588	0.00069	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—RACGAP1—polycystic ovary syndrome	0.000583	0.000685	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—INSR—polycystic ovary syndrome	0.00057	0.000669	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—ADRA1A—polycystic ovary syndrome	0.000567	0.000666	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000558	0.000654	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—FST—polycystic ovary syndrome	0.000553	0.000649	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—GAB1—polycystic ovary syndrome	0.00055	0.000645	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—ADRB2—polycystic ovary syndrome	0.00055	0.000645	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—ADRB3—polycystic ovary syndrome	0.000546	0.000641	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000541	0.000635	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—LHB—polycystic ovary syndrome	0.00054	0.000634	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000533	0.000626	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—GNRH1—polycystic ovary syndrome	0.000528	0.000619	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PGR—polycystic ovary syndrome	0.000528	0.000619	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—INSR—polycystic ovary syndrome	0.000526	0.000617	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—AKR1C1—polycystic ovary syndrome	0.000511	0.0006	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—GNAS—polycystic ovary syndrome	0.00051	0.000598	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—SCT—polycystic ovary syndrome	0.000506	0.000594	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.0005	0.000586	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—ADRB2—polycystic ovary syndrome	0.000499	0.000586	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000492	0.000577	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—GHRL—polycystic ovary syndrome	0.00049	0.000576	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PLAT—polycystic ovary syndrome	0.00049	0.000576	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PGR—polycystic ovary syndrome	0.000487	0.000571	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—MTNR1B—polycystic ovary syndrome	0.000483	0.000566	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—FGF18—polycystic ovary syndrome	0.000474	0.000557	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000473	0.000555	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—RBP4—polycystic ovary syndrome	0.00047	0.000552	CbGpPWpGaD
Vapreotide—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—polycystic ovary syndrome	0.000468	0.000549	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000468	0.000549	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—GNAS—polycystic ovary syndrome	0.000463	0.000543	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000456	0.000536	CbGpPWpGaD
Vapreotide—SSTR5—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000454	0.000533	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000453	0.000531	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000453	0.000531	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—YAP1—polycystic ovary syndrome	0.000439	0.000515	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000436	0.000512	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—GAB1—polycystic ovary syndrome	0.000433	0.000508	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000432	0.000507	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—ATF1—polycystic ovary syndrome	0.000432	0.000507	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000429	0.000504	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—PRL—polycystic ovary syndrome	0.000428	0.000502	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000421	0.000494	CbGpPWpGaD
Vapreotide—SSTR2—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.000419	0.000492	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—INSR—polycystic ovary syndrome	0.000414	0.000486	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000412	0.000484	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000406	0.000477	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000399	0.000468	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000396	0.000465	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—PRL—polycystic ovary syndrome	0.000395	0.000464	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—AKR1C3—polycystic ovary syndrome	0.000393	0.000462	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TNRC6B—polycystic ovary syndrome	0.000387	0.000455	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PGR—polycystic ovary syndrome	0.000383	0.00045	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.000381	0.000447	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000376	0.000442	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000375	0.00044	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000359	0.000421	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PLAT—polycystic ovary syndrome	0.000356	0.000418	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—GHRL—polycystic ovary syndrome	0.000356	0.000418	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000352	0.000413	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000347	0.000408	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—POMC—polycystic ovary syndrome	0.000343	0.000403	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—ATF1—polycystic ovary syndrome	0.00034	0.000399	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—TCF7L2—polycystic ovary syndrome	0.000332	0.000389	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000331	0.000388	CbGpPWpGaD
Vapreotide—TACR1—GPCR downstream signaling—AKT2—polycystic ovary syndrome	0.00033	0.000387	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000325	0.000381	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—NGFR—polycystic ovary syndrome	0.000314	0.000368	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—POMC—polycystic ovary syndrome	0.000312	0.000366	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—PRL—polycystic ovary syndrome	0.000311	0.000365	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000302	0.000354	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—AKT2—polycystic ovary syndrome	0.0003	0.000352	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—LEP—polycystic ovary syndrome	0.000295	0.000346	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—ADRB2—polycystic ovary syndrome	0.000295	0.000346	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000278	0.000327	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—GNAS—polycystic ovary syndrome	0.000274	0.000321	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—LEP—polycystic ovary syndrome	0.000272	0.00032	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000263	0.000309	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—NCOR1—polycystic ovary syndrome	0.000261	0.000306	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—NRG1—polycystic ovary syndrome	0.000256	0.0003	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—POMC—polycystic ovary syndrome	0.000253	0.000298	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—INS—polycystic ovary syndrome	0.000252	0.000296	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000244	0.000286	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000244	0.000286	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000243	0.000285	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—POMC—polycystic ovary syndrome	0.000234	0.000275	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—INS—polycystic ovary syndrome	0.000233	0.000273	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000232	0.000272	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000225	0.000264	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000225	0.000264	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IRS2—polycystic ovary syndrome	0.000219	0.000257	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—LEP—polycystic ovary syndrome	0.000214	0.000252	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000214	0.000251	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IRS1—polycystic ovary syndrome	0.000191	0.000224	CbGpPWpGaD
Vapreotide—SSTR5—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000186	0.000219	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—POMC—polycystic ovary syndrome	0.000184	0.000216	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—INS—polycystic ovary syndrome	0.000183	0.000215	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IGF1—polycystic ovary syndrome	0.000177	0.000208	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—AKT2—polycystic ovary syndrome	0.000177	0.000208	CbGpPWpGaD
Vapreotide—SSTR2—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000172	0.000202	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	0.000168	0.000197	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000159	0.000187	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000147	0.000173	CbGpPWpGaD
Vapreotide—TACR1—Signaling by GPCR—IL6—polycystic ovary syndrome	0.000135	0.000159	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—VEGFA—polycystic ovary syndrome	0.000116	0.000136	CbGpPWpGaD
Vapreotide—SSTR5—Signaling Pathways—IL6—polycystic ovary syndrome	0.00011	0.000129	CbGpPWpGaD
Vapreotide—SSTR2—Signaling Pathways—IL6—polycystic ovary syndrome	0.000102	0.000119	CbGpPWpGaD
Vapreotide—TACR1—Signaling Pathways—IL6—polycystic ovary syndrome	8e-05	9.39e-05	CbGpPWpGaD
